key: cord-0770601-itgkisy6 authors: Ho, Lee Lee; Gurung, Santosh; Mirza, Imran; Nicolas, Hemanthi Dassanayake; Steulet, Claudia; Burman, Ashley L; Danovaro-Holliday, M. Carolina; Sodha, Samir V.; Kretsinger, Katrina title: Impact of the SARS-CoV-2 pandemic on vaccine-preventable disease campaigns date: 2022-04-06 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.04.005 sha: c04e08249efa252a66c778698cea43ee5e3cf650 doc_id: 770601 cord_uid: itgkisy6 Background : The COVID-19 pandemic has contributed to the widespread disruption of immunization services, including the postponement of mass vaccination campaigns. Methods : In May 2020, the World Health Organization (WHO) and partners started monitoring COVID-19-related disruptions to mass vaccination campaigns against cholera, measles, meningitis A, polio, tetanus-diphtheria, typhoid and yellow fever through the Immunization Repository Campaign Delay Tracker. The authors reviewed the number and target population of reported preventive and outbreak response vaccination campaigns scheduled, postponed, canceled and reinstated, at four time-points: May 2020, December 2020, May 2021 and December 2021. Findings : Mass vaccination campaigns across all vaccines were disrupted heavily by COVID-19. In May 2020, 105 of 183 (57%) campaigns were postponed or canceled in 57 countries due to COVID-19, with an estimated 796 million postponed or missed vaccine doses. Campaign resumption was observed beginning in July 2020. In December 2021, 77 of 472 (16%) campaigns in 54 countries, mainly in the African Region, were still postponed or canceled due to COVID-19, with about 382 million postponed or missed vaccine doses. Interpretation : There is likely high risk of vaccine-preventable disease outbreaks due to an increased number of susceptible persons resulting from the large-scale mass vaccination campaign postponement caused by COVID-19 across all regions. In May 2020, the World Health Organization (WHO) and partners started monitoring COVID-19-related disruptions to mass vaccination campaigns against cholera, measles, meningitis A, polio, tetanus-diphtheria, typhoid and yellow fever through the Immunization Repository Campaign Delay Tracker. The authors reviewed the number and target population of reported preventive and outbreak response vaccination campaigns scheduled, postponed, canceled and reinstated, at four time-points: May 2020, December 2020, May 2021 and December 2021. Mass vaccination campaigns across all vaccines were disrupted heavily by In May 2020, 105 of 183 (57%) campaigns were postponed or canceled in 57 countries due to COVID-19, with an estimated 796 million postponed or missed vaccine doses. Campaign resumption was observed beginning in July 2020. In December 2021, 77 of 472 (16%) campaigns in 54 countries, mainly in the African Region, were still postponed or canceled due to COVID-19, with about 382 million postponed or missed vaccine doses. There is likely high risk of vaccine-preventable disease outbreaks due to an increased number of susceptible persons resulting from the large-scale mass vaccination campaign postponement caused by COVID-19 across all regions. Keywords: COVID, SARS-CoV-2 pandemic, vaccine-preventable diseases, campaign, vaccination, global The SARS-CoV-2 pandemic has brought severe disruptions to immunization activities worldwide. Independent reports from regions and countries indicated that the planning and implementation of all vaccine-preventable disease mass vaccination campaigns had been adversely affected by COVID-19, but the global impact and the progress of campaign resumption following COVID-19 disruption have not been quantified and thoroughly studied. The WHO Immunization Repository Campaign Delay Tracker has created an opportunity for the planning and execution of global vaccine-preventable diseases control/elimination/eradication programs to be tracked under one global campaign tracking mechanism. This was unprecedented and created synergistic opportunities for planning and delivery of multi-antigen campaigns. It avoids duplicated efforts for global partners in collecting updates and for countries and regions in reporting. The data collected are used for operational planning, advocacy for urgent actions to avert vaccine-preventable disease outbreaks, resource mobilization, and analysis and modeling to understand the potential impact of campaign cancelations and delays on population immunity and potential for outbreaks of highly transmissible vaccinepreventable diseases. The data and analysis presented here is by far the most comprehensive overview of how the COVID-19 pandemic affected mass vaccination campaigns. Both outbreak response and preventive mass vaccination campaigns across all vaccines were disrupted heavily by COVID-19, leaving millions of children at risk of devastating but preventable diseases. The prompt resumption of immunization activities, and an efficient catch-up strategy that aims to catch up children through a combination of enhanced routine immunization services and campaigns, is crucial to prevent the accumulation of susceptible persons and thus reduce the risk of disease outbreaks. World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020 (WHO, 2020a). By December 26, 2021, 278 million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had resulted in 5.4 million reported deaths since the start of the COVID-19 pandemic (WHO, 2021a). The pandemic has disrupted essential health services, including immunization-related activities such as preventive vaccination campaigns, outbreak response, routine immunization (fixed post and outreach) and vaccine-preventable disease (VPD) surveillance activities (WHO, 2020b (WHO, , 2020c (WHO, , 2020d Local Burden of Disease Vaccine Coverage Collaborators, 2021; Shet et al., 2021; Lassi et al., 2021) . Even a brief postponement of routine immunization activities can lead to a critical increase in the number of susceptible individuals and create immunity gaps that predispose them to VPD outbreaks within a short period of time, particularly for highly infectious diseases such as measles. In the wake of the immunization service disruptions caused by the Ebola epidemic of 2014-2015, West African countries experienced a 25% decrease in measles vaccination rate as compared to the previous years (Suk et al., 2016; Masresha et al., 2020) . Similarly, COVID-19-associated disruptions to immunization programs have the potential to reverse years of progress in VPD control worldwide. On March 24, 2020, the Polio Oversight Board (POB) of the Global Polio Eradication Initiative (GPEI) recommended pausing all polio campaigns until June 1, 2020, given the uncertainties associated with the pandemic (GPEI, 2020). The same month, the Strategic Advisory Group of Experts on Immunization (SAGE) advising the WHO recommended temporarily suspending mass vaccination campaigns due to the risk of SARS-CoV-2 transmission and advised countries to monitor and re-evaluate at regular intervals the risks and benefits of delaying mass vaccination campaigns (WHO, 2020e). As the negative impact of disrupted essential health services, including immunization, on public health became evident, WHO developed guidance to promote safe practices during vaccination activities based on an improved understanding of SARS-CoV-2 transmission (WHO, 2020f, 2020g, 2020h,2020i) . SAGE subsequently urged and reinforced countries to preserve mass vaccination campaigns and prioritize the implementation of catch-up vaccination policies and strategies where appropriate (WHO, 2020j, 2020k) . Beginning in May 2020, WHO, in collaboration with partners, tracked and monitored the impact of COVID-19-related disruptions on preventive and outbreak response vaccination campaigns. The authors describe here the systems put in place and the trends in campaign postponement and resumption since the COVID-19 pandemic began to disrupt programmatic activities and the campaign monitoring in May 2020 through December 2021. WHO and partners established an online repository Campaign Delay Tracker in May 2020, using an existing WHO Immunization Repository Platform. The tracker includes campaigns with the following vaccines: measles-containing vaccines (MCV) including measles, measles-rubella (MR) or measles-mumps-rubella (MMR) vaccines; bivalent oral polio vaccine types 1 and 3 (bOPV); monovalent oral polio vaccine OPV type 2 (mOPV2); inactivated polio vaccine (IPV); meningitis A conjugate vaccine (MenA); tetanus-diphtheria vaccine (Td); yellow fever vaccine (YF); typhoid conjugate vaccine (TCV) and oral cholera vaccine (OCV). Trivalent oral polio vaccines (tOPV) and novel oral polio vaccine type 2 (nOPV2) were added to the analysis starting in 2021, tOPV was reintroduced due to the dual threat of different strains of poliovirus and mOPV2 was replaced by nOPV2 in some vaccination campaigns. Additional variables collected for each campaign included the following: WHO and UNICEF Region, country, the geographic scope of the campaign (national or sub-national), original implementation date, postponed implementation date, target population age range and size, type of vaccination campaign (preventive or outbreak response), funding source, and other services including co-administered vaccines or other health interventions. The status for each campaign activity was classified into one of the following categories: -on track‖, refers to campaigns that had proceeded or would proceed on time as planned or with slight postponement of less than one month; -postponed COVID‖, campaigns with confirmed delay fully or partially due to COVID-19 related reasons such as programmatic challenges of campaign implementation in the COVID-19 context or competing priorities with COVID-19 response activities or COVID-19 vaccine rollout; -postponed other‖, campaigns with confirmed delay due to non-COVID-19 reasons; -canceled‖, campaigns which have been canceled and will not be implemented in the foreseeable future; -reinstated COVID‖, campaigns which were previously postponed fully or partially due to COVID-19 but were subsequently implemented; -reinstated others‖, campaigns which were previously postponed due to non-COVID-19 reasons but were subsequently implemented; -unknown‖, campaigns with no information received on whether they will be implemented or had been implemented on time or postponed. WHO Headquarters received updates on the campaigns through reports, teleconferences, and email exchanges with partners and regional and country colleagues, as well as direct country reports. The bOPV, mOPV2, tOPV and nOPV2 data were extracted from the Polio Information System (POLIS) to the tracker. POLIS is an integrated approach to polio real-time data management, whereby data from member states are collected, consolidated, harmonized and made available for dissemination and analysis for GPEI partners and modelers. Given the complexity and dynamic characteristic of polio vaccination campaigns with bOPV, mOPV2, tOPV and nOPV2, the data of these four vaccines in this manuscript were cleaned and analyzed separately by the POLIS focal point (ALB). The total number of campaigns reflected in the tracker increased over time as countries made formal plans to conduct campaigns. With 2021 planned campaign data added to the Campaign Delay Tracker in late January 2021, the February 1, 2021, repository data reflected a sudden increase in the total number of campaigns. The tracker was updated biweekly until June 2021, and then monthly, to reflect these updates, and the extracted data were disseminated to a wide range of immunization partners. Datapoints reflecting prior campaign status were updated retrospectively as new data became available; hence, the final database used for this analysis may not completely match the data in the partner reports. The data presented here are subject to several limitations. The Campaign Delay Tracker contains information obtained from various sources, not only data officially reported by the WHO Member States. Hence some data may be incomplete or erroneous. In addition, the data are evolving dynamically and reflect programmatic decisions taken at the country level to schedule, postpone, implement and/or cancel campaign activities. New data and corrections were entered as new updates came in, resulting in shifting denominators. Furthermore, the data on vaccination doses are approximate and do not represent unique individuals but rather the number of vaccines to be administered. disruptions brought to other vaccine-preventable diseases. Because COVID-19 vaccines had received WHO's Emergency Use Listing in December 2020 and very few low and middle-income countries had started using COVID-19 by March 2021, we excluded COVID-19 vaccine data from this study. Furthermore, it is challenging to compare the Campaign Delay Tracker data with COVID-19 data from WHO COVID-19 Dashboard and Our World in Data, which targets the number of cases and vaccinations but not the trend of campaign implementation, postponement or cancellation. A baseline analysis of campaign postponement and cancellation prior to COVID-19 is not feasible due to missing historical data on campaigns disruptions at the global level. Nevertheless, the data and analysis presented here is the most comprehensive overview of how the COVID-19 pandemic affected vaccination campaigns, which are a broadly used strategy to supplement routine immunization and respond to VPD outbreaks, especially in settings where the routine immunization programs fail to reach very high vaccination coverage levels. As of May 15, 2020, 105 of 183 (57%) campaigns with a previously planned implementation date from March to December 2020 were postponed or canceled due to COVID-19; 13 (4 bOPV, 4 mOPV2, 2 Td, 2 IPV, 1 Men A) were postponed or canceled due to reasons other than COVID-19; 24 (5 bOPV, 5 mOPV2, 4 MCV, 4 Td, 3 IPV, 1 MenA, 1 OCV, 1YF) were on track and the status of 41 (17 MCV, 11 IPV, 8 bOPV, 2 YF, 1 MenA, 1 TCV, 1 Td) was considered unknown. The 105 campaigns postponed or canceled due to COVID-19 affected 57 countries and resulted in an estimated 796 million postponed or missed vaccine doses. Forty (38%) campaigns were for outbreak response. As of December 15, 2020, 77 of 292 (26%) campaigns with a previously planned implementation date from March to December 2020 were postponed or canceled due to 41 (15 bOPV, 14 mOPV2, 4 MCV, 4 MenA, 2 IPV, 2 Td) were postponed or canceled due to non-COVID-19 reasons, 52 (19 mOPV2, 12 MCV, 8 YF, 5 Td, 3 bOPV, 3 IPV, 1 Men A, 1 OCV) were reinstated following postponement due to COVID-19, 6 (2 mOPV2, 2 MCV, 1 IPV, 1 OCV) were reinstated after non-COVID disruptions. Ninetyfour campaigns (48 mOPV2, 25 bOPV, 11 MCV,4 OCV, 3 Td, 2 IPV, 1 YF) were on track and the status of 22 campaigns (7 IPV, 5 bOPV, 4 mOPV2, 3 MCV, 1 MenA, 1 OCV, 1 Td) was considered unknown. The 77 campaigns postponed or canceled due to COVID-19 were in 50 countries and resulted in an estimated 365 million postponed or missed vaccine doses. Nineteen (25%) campaigns were outbreak response immunization. An increasing number of previously postponed campaigns due to COVID-19 took place starting from mid-July 2020. As of December 15, 2020, 52 of 106 (49%) of the VPD campaigns which had initially been planned to take place between March and December 2020 had been reinstated following a postponement caused by COVID-19. In total, the delivery of approximately 333 million vaccine doses were resumed in 2020. As of May 15, 2021, 79 of 386 (20%) campaigns with a previously planned implementation date from March 2020 to December 2021 were postponed or canceled due to COVID-19, 53 (21 bOPV, 19 mOPV2, 4 IPV, 3 MCV, 2 MenA, 2 OCV, 2 Td) were postponed or canceled due to non-COVID reasons; 72 (22 mOPV2, 21 MCV, 13 YF, 5 IPV, 5 Td, 3 bOPV, 1 Men A, 1 OCV, 1 TCV) campaigns were reinstated following postponement due to COVID-19; 14 (5 mOPV2, 3 MCV, 3 IPV, 2 bOPV, 1 YF) were reinstated after non-COVID disruptions. Then 136 (67 mOPV2, 29 bOPV, 12 MCV,7 tOPV, 7 OCV, 5 nOPV2, 5 YF, 3 Td, 1 Men A) were on track and the status of 32 campaigns (16 MCV, 10 bOPV, 3 mOPV2, 1 IPV, 1 OCV, 1Td) was considered unknown. The 79 campaigns which were postponed or canceled due to COVID-19 were in 53 countries and resulted in an estimated 390 million postponed or missed vaccine doses. Twelve (15%) were outbreak responses. As of May 15, 2021, 72 of 128 (56%) VPD campaigns which were initially planned to take place at some time between March 2020 and December 2021 had been reinstated following an initial postponement caused by COVID-19. In total, the delivery of accumulated 433 million vaccine doses was resumed. As of December 1, 2021, 77 of 472 (16%) campaigns with a previously planned implementation date from March 2020 to December 2021 were postponed or canceled due to 76 (23 bOPV, 19mOPV2, 12 Seventy-six of 128 (59%) VPD campaigns which were initially planned to take place at some time between March 2020 and December 2021 had been reinstated following an initial postponement caused by COVID-19. In total, the delivery of accumulated 478 million vaccine doses was resumed. Our results indicate that both outbreak response and preventive campaigns across all The accrued learning about transmission risk resulted in guidance measures that were updated during the pandemic and reflected in the resumption of campaign activities. Research shows that with appropriate precautions, there would be minimal risk for SARS-CoV-2 transmission during VPD campaigns (WHO, 2020l). In October 2020, the WHO again emphasized the need to rapidly restore campaigns, immunization clinics and outreach activities, in order to prevent outbreaks and deaths from VPDs (WHO, 2020m). WHO and UNICEF issued an emergency call to action in November 2020 to avert major measles and polio epidemics as COVID-19 continued to disrupt immunization services worldwide, leaving millions of children at heightened risk of preventable childhood disease (UNICEF and WHO, 2020). Based on country experiences on immunization activities during COVID-19, multi-antigen or integrated mass intervention campaigns should be considered to maximize efficiencies. Digital tools facilitate the use of real-time data for campaign planning (UNICEF, 2021). The prompt resumption of immunization activities, and an efficient catch-up strategy that aims to catch up children through a combination of enhanced routine immunization services and campaigns, is crucial to prevent the accumulation of susceptible persons, especially with the anticipation of near-term events that may again disrupt immunization systems, including new waves of genetically evolving SARS-CoV-2 variants and the introduction of COVID-19 vaccines. There are opportunities to learn from multiple success stories of campaigns successfully conducted during the pandemic. For example, Nepal was the first country to conduct a mass measles vaccination campaign during the pandemic (WHO, 2020n). Ethiopia vaccinated 14.5 million children amidst COVID-19 community circulation and conflict. Thanks to a strong coordination mechanism, effective community engagement, and innovative vaccination delivery strategies, the campaign attained 96% coverage (WHO, 2020o) . Sudan implemented an innovative and integrated approach to combine catchup activities for children in host communities with the vaccination for refugees (EYE, 2020) . Increasing numbers of countries have re-instated campaigns with multiple antigens, adjusted to the current circumstances and each local context. However, conducting campaigns and immunization services during COVID-19 is not without challenges. The planning and implementation of these campaigns are still adversely affected by the COVID-19 pandemic. Current data indicate that the pandemic has continued to limit the quality of immunization activities and surveillance sensitivity. Personnel and resources are stretched to cover the increased demand for COVID-19 diagnoses. Some countries have prioritized COVID-19 vaccine rollout over other vaccination campaigns. Although the use of resources has been reprogramed from other VPD campaigns to COVID-19 campaigns, this analysis did not track the implementation of COVID-19 campaigns enabled by this reprogramming. Public health and coordination structures have been shifted to COVID-19 control. Global attention and additional resources are still urgently needed to address dangerous immunity gaps across all VPDs. As stated by the Independent Panel on Pandemic Preparedness and Response, investment in strengthening health system resilience is essential in preparation for future health threats like COVID-19 (WHO, 2021c). The WHO Campaign Delay Tracker has created an opportunity for all global VPDs control/elimination/eradication programs to have one global campaign tracking mechanism. This was unprecedented and created synergistic opportunities for planning and delivery of multi-antigen campaigns. The WHO Campaign Delay Tracker serves as a centralized database for monitoring preventive and outbreak response vaccination campaigns, documenting postponements, and providing data for the purpose of partner coordination and programmatic monitoring. The data were also used to inform analysis and modeling to understand the potential impact of campaign cancelations and delays on population immunity and the potential for outbreaks of highly transmissible VPDs (Gaythorpe, 2021) , with modeling studies quantifying the impact of campaign delays (Gaythorpe, 2021; Kalkowska, 2021) . The lessons learned from establishing the Campaign Delay Tracker illustrate the importance of clearly defining each variable to minimize information bias caused by different categorizations of campaign status or other variables. The methodology used and limitations of the analysis need to be clearly stated and well communicated with immunization partners to avoid misinterpretations. Building synergies with other campaign data systems is crucial to avoid duplicated data collection and management efforts. Between May 2020 and December 2021, the implementation of a significant number of vaccination campaigns was adversely affected by the COVID-19 pandemic. As a consequence, a large number of persons susceptible to VPDs has been and is likely accumulating, and thus the risk of VPD outbreaks is high. Delaying outbreak response is likely to result in a more immediate increase in cases and deaths than delaying preventive campaigns. As mass immunization campaigns have gotten delayed, some children mature out of the target age, thus remaining unexposed to additional vaccination opportunities. At the writing of this paper, some vaccinations have resumed and are being implemented across Member States, with infection prevention and control (IPC) measures in place and with a move towards increased integration. This gradual resumption is a testament to the work of countries to protect their populations against VPDs. It is still crucial to urgently reduce the remaining immunity gaps caused by disrupted immunization services to prevent extensive VPD outbreaks under a health system already strained by the COVID-19 pandemic. a The cumulative number of campaigns reinstated following an initial postponement caused by monovalent oral poliovirus type2 (mOPV2), 38% (3/8) bivalent oral poliovirus types 1&3 (bOPV) and 25% (3/12) inactivated polio vaccine (IPV) campaigns were reinstated following postponement due to This column includes those campaigns which had ever been postponed at any point between March and December 2020 and represents the cumulative number of reinstated campaigns plus the number of campaigns that were still being postponed/ projected to be postponed due to COVID-19, as of December 2020. a The cumulative number of campaigns reinstated following an initial postponement caused by 100% (22/22) monovalent oral poliovirus type2 (mOPV2), 50% (3/6) bivalent oral poliovirus types 1&3 (bOPV) and 28% (5/18) inactivated polio vaccine (IPV) campaigns were reinstated following postponement due to . No trivalent oral polio vaccine (tOPV) or novel oral polio vaccine type 2 (nOPV2) campaign was recorded as -postponed COVID‖ or -reinstated COVID‖ c This column includes those campaigns which had ever been postponed at any point between March 2020 and December 2021 and represent the cumulative number of reinstated campaigns plus the number of campaigns that were still being postponed/ projected to be postponed due to COVID-19, as of December 2021. Note: This figure depicts the total number of campaigns that had previously been planned to take place, but which were projected to be postponed due to . Campaigns which had been reinstated, even if implementation was delayed from the originally planned date, were removed from the postponement tally. This graph does not include the number of campaigns which were postponed due to non-COVID related reasons or the number of canceled campaigns. No trivalent oral polio vaccine (tOPV) or novel oral polio vaccine type 2 (nOPV2) campaign was recorded as "postponed COVID". Routine childhood immunization during the COVID-19 pandemic in AFRICA: A benefit-risk analysis of health benefits Versus excess risk of Sars-cov-2 infection. The Lancet Global Health Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modeling study Progress Toward Polio Eradication -Worldwide EYE newsletter Polio Eradication in the Context of the COVID-19 Pandemic: Summary of urgent country and regional recommendations from the Polio Oversight Board meeting of The impact of disruptions caused by the COVID-19 pandemic on global polio eradication Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response The Impact of the COVID-19 Pandemic on Immunization Campaigns and Programs: A Systematic Review Mapping routine measles vaccination in low-and middle-income countries Reducing Childhood Immunization to Scale Up COVID-19 Immunization in Low-and Lower Middle-Income Countries: Impact on Under-Five Mortality The impact of a prolonged Ebola outbreak on measles elimination activities in Guinea Impact of the SARS-CoV-2 pandemic on routine immunization services: evidence of disruption and recovery from 170 countries and territories Emerging infectious diseases who-call-for-emergency-action-to-avert-major-measles-and-polio-epidemics#:~:text=UNICEF%20and%20the%20World%20Health,risk%20of%20prevent able%20childhood%20diseases Lessons Learned and Good Practices. Country-Specific Case Studies on Immunization Activities During the COVID-19 Pandemic WHO Director-General's opening remarks at the media briefing on COVID-19 Understanding the disruption to programs through rapid polling Special feature: immunization and COVID-19 Pulse survey on continuity of essential health services during the Covid Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance WHO 2020f Immunization in the context of COVID-1 pandemic frequently asked questions FA Maintaining essential health services: operational guidance for the COVID-19 context: interim guidance Framework for decision-making: implementation of mass vaccination campaigns in the context of COVID-19: interim guidance Leave no one behind: guidance for planning and implementing catch-up vaccination Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption Meeting of the Strategic Advisory Group of Experts on Immunization The risk of SARS-CoV-2 transmission to communities and to health workers in LMICs under different health service delivery conditions WHO director-general's opening remarks at the media briefing on covid-19 COVID-1 WHO's Action in Countries July feature countries A monthly selection of case studies Ethiopia vaccinates nearly 15 million children against measles despite Covid-19 challenges World Health Organization Coronavirus (COVID-19 Immunization, Vaccines, Biologicals. Progresses and Challenges with Sustaining and Advancing Immunization Coverage During the COVID-19 Pandemic 2021 Health Systems Resilience during COVID-19: Lessons for building back better The authors wish to thank all the persons that make immunization possible, even under challenging circumstances like the current COVID-19 pandemic. Additional thanks go to The authors declare no competing interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have read and complied with the policy stated in Ethics in publishing.